Boston Partners cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 25.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,772,398 shares of the biopharmaceutical company’s stock after selling 2,652,391 shares during the period. Boston Partners owned about 0.60% of Gilead Sciences worth $556,815,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. Welch Investments LLC bought a new position in Gilead Sciences during the third quarter valued at $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences during the third quarter valued at $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences during the third quarter valued at $144,000. Hanson & Doremus Investment Management grew its holdings in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences during the second quarter valued at $147,000. 77.96% of the stock is owned by institutional investors.
GILD has been the subject of several research reports. Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and increased their price objective for the company from $73.25 to $73.77 in a report on Monday, November 13th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $73.67 to $94.00 in a report on Thursday, November 30th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. Finally, Oppenheimer reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, December 21st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus price target of $87.75.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter last year, the business posted $2.70 earnings per share. The firm’s revenue was down 18.7% compared to the same quarter last year. analysts expect that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 27.05%.
In related news, CFO Robin L. Washington sold 5,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares in the company, valued at $1,907,282.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders sold 424,435 shares of company stock worth $33,602,330 in the last quarter. 1.30% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/13/gilead-sciences-inc-gild-stake-lessened-by-boston-partners.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.